![]() |
Name |
3,7,11-Trimethyl-1-dodecanol
|
Molecular Formula | C15H32O | |
IUPAC Name* |
3,7,11-trimethyldodecan-1-ol
|
|
SMILES |
CC(C)CCCC(C)CCCC(C)CCO
|
|
InChI |
InChI=1S/C15H32O/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16/h13-16H,5-12H2,1-4H3
|
|
InChIKey |
HDPUXESLSOZSIB-UHFFFAOYSA-N
|
|
Synonyms |
3,7,11-Trimethyl-1-dodecanol; hexahydrofarnesol; 6750-34-1; 3,7,11-trimethyldodecan-1-ol; 1-Dodecanol, 3,7,11-trimethyl-; 1-Dodecanol,3,7,11-trimethyl-; Hexa-hydro-farnesol; 66J3UW66VV; FARNESANOL; 3,7,11-trimethyldodecanol; UNII-66J3UW66VV; SCHEMBL95500; QSPL 138; CHEBI:84239; DTXSID70880730; 1-Dodececanol,3,7,11-trimethyl; FT-0737188; EN300-135888; Q27157608
|
|
CAS | 6750-34-1 | |
PubChem CID | 138824 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 228.41 | ALogp: | 6.1 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 20.2 | Aromatic Rings: | 0 |
Heavy Atoms: | 16 | QED Weighted: | 0.552 |
Caco-2 Permeability: | -4.273 | MDCK Permeability: | 0.00001410 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.277 |
30% Bioavailability (F30%): | 0.652 |
Blood-Brain-Barrier Penetration (BBB): | 0.321 | Plasma Protein Binding (PPB): | 96.98% |
Volume Distribution (VD): | 1.74 | Fu: | 2.44% |
CYP1A2-inhibitor: | 0.677 | CYP1A2-substrate: | 0.215 |
CYP2C19-inhibitor: | 0.302 | CYP2C19-substrate: | 0.327 |
CYP2C9-inhibitor: | 0.547 | CYP2C9-substrate: | 0.932 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.049 |
CYP3A4-inhibitor: | 0.064 | CYP3A4-substrate: | 0.133 |
Clearance (CL): | 9.13 | Half-life (T1/2): | 0.149 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.042 |
Drug-inuced Liver Injury (DILI): | 0.041 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.011 | Maximum Recommended Daily Dose: | 0.021 |
Skin Sensitization: | 0.931 | Carcinogencity: | 0.049 |
Eye Corrosion: | 0.986 | Eye Irritation: | 0.97 |
Respiratory Toxicity: | 0.162 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000537 | ![]() |
0.792 | D00FSV | ![]() |
0.411 | ||
ENC000766 | ![]() |
0.745 | D03LGY | ![]() |
0.247 | ||
ENC000536 | ![]() |
0.729 | D0D9NY | ![]() |
0.205 | ||
ENC000538 | ![]() |
0.704 | D0X4FM | ![]() |
0.204 | ||
ENC001286 | ![]() |
0.679 | D0K5WS | ![]() |
0.198 | ||
ENC001722 | ![]() |
0.667 | D0ZI4H | ![]() |
0.196 | ||
ENC000354 | ![]() |
0.644 | D0N3NO | ![]() |
0.194 | ||
ENC000441 | ![]() |
0.644 | D0K3ZR | ![]() |
0.189 | ||
ENC000622 | ![]() |
0.627 | D00WUF | ![]() |
0.183 | ||
ENC000627 | ![]() |
0.613 | D05QNO | ![]() |
0.182 |